DX
Disease Management, Imaging and Therapeutics
Friday, May 26, 2017: 2:00 PM-4:00 PM
R06 (New Orleans Convention Center)
2:00 PM
Rapid and Robust B Cell Depletion in Preliminary Results of a Phase 2 Study of Ublituximab, Novel Glycoengineered Anti-CD20 Mab, in RMS Patients
Amy Lovett-Racke, PhD, Ohio State University Medical Center;
Yue Liu, MS, Ohio State University Medical Center;
Michael K Racke, MD, Wexner Medical Center, Ohio State University;
Sibyl Wray, MD, Hope Neurology Multiple Sclerosis Center;
Richard Shubin, MD, SC3 Research Group, Inc;
Cary L Twyman, MD, Associates in Neurology PSC, Lexington, KY, USA;
Wendy Su, PhD, TG Therapeutics;
James Eubanks, PhD, TG Therapeutics, Inc;
Edward J. Fox, MD, PhD, Central Texas Neurology Consultants;
Wendy Su, PhD, TG Therapeutics, Inc
2:17 PM
Durable Efficacy of Alemtuzumab on Clinical and MRI Outcomes over 6 Years in Care-MS II Patients with Active RRMS with Relapse Between Courses 1 and 2
Barry A Singer, MD, MS Center for Innovations in Care, Missouri Baptist Medical Center;
Simon Broadley, MD, School of Medicine, Gold Coast Campus, Griffith University;
Angel Chinea, MD, San Juan Multiple Sclerosis Center;
Mark S Freedman, MD, University of Ottawa and the Ottawa Hospital Research Institute;
Guillermo Izquierdo, MD, Virgen Macarena University Hospital;
Jan Lycke, MD, Sahlgrenska University Hospital;
Basil Sharrack, MD, PhD, Sheffield Teaching Hospitals NHS Foundation Trust;
Brian Steingo, MD, Fort Lauderdale Multiple Sclerosis Center;
Heinz Wiendl, MD, University of Munster;
Sibyl Wray, MD, Hope Neurology Multiple Sclerosis Center;
David H Margolin, MD, PhD, Sanofi Genzyme;
Sourav Santra, PhD, Cytel;
Karthinathan Thangavelu, PhD, Sanofi Genzyme;
Aaron Boster, MD, OhioHealth Neurological Physicians;
on behalf of the CARE-MS II and CAMMS03409 Investigators, n/a, N/A
2:34 PM
When Should Disease-Modifying Treatments be Discontinued in Patients with Multiple Sclerosis: An Evidence-Based Review with Expert Recommendations
Devyn Parsons, BSc, University of British Columbia;
Virginia Devonshire, MD, University of British Columbia;
Robert Carruthers, MD, University of British Columbia;
Lorne Kastrukoff, MD, University of British Columbia;
Anthony Traboulsee, MD, University of British Columbia;
Devyn Parsons, BSc, University of British Columbia
2:51 PM
Benefits of Cladribine Tablets in Patients with Multiple Sclerosis Free from Clinical and Radiological Indicators of Disease Activity in the CLARITY EXTENSION Study
Gavin Giovannoni, MD, Queen Mary University of London, Blizard Institute, Barts and The London School of Medicine and Dentistry;
Giancarlo Comi, MD, University Vita-Salute San Raffaele;
Stuart Cook, MD, Rutgers, The State University of New Jersey;
Peter Rieckmann, MD, Akademisches Krankenhaus Sozialstiftung Bamberg;
Kottil Rammohan, MD, Ohio State University Hospital;
Per Soelberg-Sorensen, MD, Copenhagen University Hospital;
Patrick Vermersch, MD, University of Lille;
Abidemi Adeniji, PhD, EMD Serono, Inc.;
Fernando Dangond, MD, EMD Serono, Inc.;
Mary Lee, NA, Caudex;
Michele Springer, BA, Caudex
3:08 PM
Efficacy and Safety of Ozanimod in the Blinded Extension (120 weeks) of RADIANCE, a Phase 2 Trial in Relapsing Multiple Sclerosis
Giancarlo Comi, MD, Vita-Salute San Raffaele University;
Douglas L Arnold, MD, Montreal Neurological Institute, McGill University;
Amit Bar-Or, MD, Montreal Neurological Institute and Hospital McGill University;
Krzysztof W Selmaj, MD, PhD, Medical Academy of Lodz;
Lawrence Steinman, MD, Stanford University School of Medicine;
Eva K Havrdova, MD, PhD, Charles University;
Bruce AC Cree, MD, PhD, University of California;
Hans-Peter Hartung, MD, Heinrich-Heine-University Dusseldorf;
Ludwig Kappos, MD, University of Basel;
Brett E Skolnick, PhD, Receptos Services LLC;
Jeffrey A Cohen, MD, Mellen Center U-10 Cleveland Clinic;
Jacqueline Marut, BA, NA
3:25 PM
Preliminary Results of the OPERA I and OPERA II Open-Label Extension Study
Robert T Naismith, MD, Washington University School of Medicine;
Mark Cascione, MD, Axiom Clinical Research of Florida;
Luigi ME Grimaldi, MD, Fondazione Istituto - G. Giglio;
Stephen L Hauser, MD, University of California, San Francisco;
Ludwig Kappos, MD, University Hospital Basel, University of Basel;
Xavier Montalban, MD, PhD, Vall d'Hebron University Hospital;
Jerry S Wolinsky, MD, McGovern Medical School, UTHealth;
Peter Chin, MD, Genentech Inc.;
Hideki Garren, PhD, MD, Genentech Inc.;
Laura Julian, PhD, Genentech, Inc.;
Fabian Model, PhD, F. Hoffmann-La Roche Ltd;
David Honeycutt, MD, Neurology Associates P.A., Multiple Sclerosis Center of Greater Orlando;
Robert T Naismith, MD, Washington University School of Medicine
